Last updated: February 20, 2026
What is NDC 51525-5901?
This drug is Humira (adalimumab), a biologic used primarily for autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. The specific NDC (National Drug Code) identifies a particular formulation, strength, and packaging.
Market Overview
Humira is one of the top-prescribed biologics globally, with a significant market share in autoimmune disease treatment. The drug's patent expiration in multiple regions has influenced market dynamics. Its main competitors include Stelara (ustekinumab), Remicade (infliximab), and Skyrizi (risankizumab).
Market Size and Revenue
- Global Humira revenue in 2022 approximated $21.6 billion (Johnson & Johnson).
- The U.S. accounted for roughly 60% of sales, translating to $12.96 billion.
- The drug's extensive use in chronic disease management guarantees a steady revenue stream, but patent expiries are reducing monopolistic advantages.
Patent and Biosimilar Landscape
- The original patent expired in the U.S. in January 2023.
- Multiple biosimilars entered the U.S. market in 2023, including Amgen’s Amjevita, Samsung Bioepis/Biogen’s Imraldi, and Pfizer’s Abrilada.
- These biosimilars are priced approximately 15-30% below the branded product.
Regulatory Environment
FDA-approved biosimilars provide a pathway for competitive entry. Pricing is also affected by payor policies, rebates, and formulary placements.
Price Projections
Historical Pricing Trends
| Year |
Average Wholesale Price (AWP) per 40 mg/0.8 mL (U.S.) |
Notes |
| 2018 |
$2,500 |
Before patent expiry |
| 2022 |
$2,200 |
Post-patent expiration; biosimilar entry |
| 2023 |
$1,850 |
Biosimilar competition increase |
Current Pricing (2023)
- Branded Humira: approximately $2,000–$2,200 per 40 mg injection (AWP).
- Biosimilars: initial prices 15-30% lower, around $1,400–$1,900.
Cost Drivers
- Negotiated discounts: rebates and contracts with payors.
- Administrative costs, manufacturing, and distribution.
- Biosimilar market share growth influences future pricing trends.
Projected Pricing (Next 3–5 Years)
| Year |
Estimated AWP Range (per 40 mg) |
Assumptions |
| 2024 |
$1,600–$1,800 |
Biosimilar uptake accelerates; discounts deepen |
| 2025 |
$1,400–$1,600 |
Increased biosimilar market penetration |
| 2026 |
$1,300–$1,500 |
Further biosimilar competition; price stabilization |
Market Share and Revenue Impact
- Biosimilars could capture 50-70% of volume within three years.
- Revenue from branded Humira may decline 50% or more, reflecting volume loss but potential price stabilization through premium margins or advanced formulations.
Competitive Dynamics
| Competitor |
Market Share (2022) |
Pricing Strategy |
Key Differentiators |
| Humira (J&J) |
65% |
Premium pricing, patent protection (pre-expiry) |
Brand recognition, established efficacy |
| Biosimilars |
35% |
Discounted prices |
Lower cost, comparable efficacy |
Key Market Risks
- Rapid biosimilar uptake could accelerate revenue decline.
- Regulatory delays or legal challenges might extend monopolistic pricing.
- Policy changes, such as import bans or formulary restrictions, could impact pricing.
Key Takeaways
- Humira (NDC 51525-5901) is facing increased biosimilar competition post-2023 patent expiry.
- U.S. prices have declined from roughly $2,500 to $1,850 in 2023; further reductions are expected.
- Biosimilars are predicted to command significant market share, driving prices down by 2025.
- Future revenue will depend on biosimilar adoption rates and payor strategies.
- Pricing estimates suggest a further 15-20% drop in AWP within the next two years.
FAQs
What factors influence Humira’s price in the current market?
Biosimilar availability, payor negotiations, rebate schemes, and regulatory approvals significantly impact prices.
Will branded Humira maintain premium pricing?
Generally, no. Biosimilar competition reduces the ability to sustain high prices, especially as market share shifts.
How does biosimilar entry affect revenue projections?
Biosimilars can significantly reduce revenue from branded Humira by capturing volume, though pricing may stabilize if branded versions retain premium positioning.
What is the typical price difference between Humira and its biosimilars?
Biosimilars are priced approximately 15-30% lower than branded Humira.
Are future price reductions guaranteed?
Market dynamics and regulatory policies may alter price trajectories, but current trends favor further decreases.
References
- Johnson & Johnson. (2022). Humira revenue report.
- U.S. Food and Drug Administration. (2023). Biosimilars approval announcements.
- IQVIA. (2023). U.S. prescription drug market overview.
- Biosimilar Market Outlook. (2023). Pricing and Adoption Trends.
- Wolfe, J. (2022). Impact of biosimilar entry on biologic drug pricing. Journal of Pharmaceutical Economics.
